Neuro-oncology
Clinical research includes treatment-focused studies in recurrent grade 3 and grade 4 glioma, with attention to therapeutic activity and tolerability in aggressive central nervous system tumours. The sponsor also supports work using PSMA theranostics in this setting.
- Recurrent high-grade glioma
- 177Lu-PSMA and 68Ga/177Lu-PSMA approaches
- Safety and efficacy in brain tumour treatment
These activities reflect interest in advanced radioligand-based strategies for difficult-to-treat malignant brain disease.
Thoracic oncology
The sponsor funds studies in small-cell lung cancer, including both limited disease and extensive stage settings. Research centres on combining immunotherapy, chemotherapy, and thoracic radiotherapy to improve survival outcomes.
- Limited disease small-cell lung cancer
- Extensive stage small-cell lung cancer
- Atezolizumab, durvalumab, and thoracic radiotherapy
Research in this area emphasizes treatment intensification and multimodal care for high-risk lung cancer.
Neurological pain disorders
Clinical work includes intervention studies in refractory chronic cluster headache, with a focus on targeting the sphenopalatine ganglion using botulinum toxin and image-guided delivery techniques. The research addresses persistent headache symptoms that are difficult to manage with standard therapy.
- Chronic cluster headache
- Sphenopalatine ganglion targeting
- Botulinum toxin treatment strategies
This area links pain neurology with procedural and device-assisted treatment development.
Endocrinology and autoimmune diabetes
Research activity also extends to Latent Autoimmune Diabetes in Adults (LADA), with interest in beta cell function, metabolic control, and HLA-DR3DQ2 status after GAD-alum treatment. The sponsor’s work examines immune-mediated diabetes progression and long-term disease status.
- LADA
- Beta cell function and metabolic control
- HLA-associated autoimmune diabetes
These studies focus on the interface between immunology, glycaemic regulation, and adult-onset autoimmune diabetes.
Alzheimer’s disease
The sponsor is involved in research on the early symptomatic phase of Alzheimer’s disease, supporting clinical investigation in neurodegenerative disease and early-stage cognitive decline.
- Early symptomatic Alzheimer’s disease
- Neurodegeneration
- Cognitive impairment
This field adds a neurodegenerative dimension to the sponsor’s broader clinical portfolio.
